Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice

Endocrinology

Volumn 153, Issue 6, 2012, Pages 2623-2632

  Yusta, Bernardo ^a   Holland, Dianne ^a   Waschek, James A ^b   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLUCAGON LIKE PEPTIDE 2; RNA; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CELL PROTECTION; COLITIS; COLON; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INTESTINE CELL; INTESTINE CRYPT; INTESTINE INNERVATION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; TREATMENT OUTCOME; WEIGHT REDUCTION; WESTERN BLOTTING;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; COLON; ENTERIC NERVOUS SYSTEM; FEMALE; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 2; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTESTINE, SMALL; INTESTINES; JEJUNUM; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN SIZE; PANETH CELLS; RECEPTORS, GLUCAGON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX FACTORS; SIGNAL TRANSDUCTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84861309089     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1069     Document Type: Article

References (46)

1. Drucker DJ 2002 Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-544 (Pubitemid 34117003)
2. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF 1986 Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880-11889 (Pubitemid 17206117)
3. Orskov C, Holst JJ, Poulsen SS, Kirkegaard P 1987 Pancreatic and intestinal processing of proglucagon in man. Diabetologia 30:874-881 (Pubitemid 18003670)
4. Burcelin R 2010 The gut-brain axis: a major glucoregulatory player. Diabetes Metab 36(Suppl 3):S54-S58
5. Lovshin JA, Drucker DJ 2009 Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269
6. Brubaker PL, Izzo A, Hill M, Drucker DJ 1997 Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 272:E1050-E1058
7. Drucker DJ, Erlich P, Asa SL, Brubaker PL 1996 Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93:7911-7916 (Pubitemid 26277138)
8. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM 2009 Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:1091-1103
9. Ivory CP, Wallace LE, McCafferty DM, Sigalet DL 2008 Interleukin-10- independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 295:G1202-G1210
10. L'Heureux MC, Brubaker PL 2003 Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther 306:347-354 (Pubitemid 36734391)
11. Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA 2007 Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 293:G211-G221 (Pubitemid 47105173)
12. Arthur GL, Schwartz MZ, Kuenzler KA, Birbe R 2004 Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. J Pediatr Surg 39:448-452; discussion 448-452
13. Boushey RP, Yusta B, Drucker DJ 1999 Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 277:E937-E947
14. Boushey RP, Yusta B, Drucker DJ 2001 Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 61:687-693 (Pubitemid 32128634)
15. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL 1999 Human [Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 276:G79-G91 (Pubitemid 29063603)
16. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ 2011 Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 60:902-914
17. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG 2010 Teduglutide, a novel mucosally active analog of glucagon-like peptide- 2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 16:962-973
18. Rowland KJ, Brubaker PL 2011 The "cryptic" mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 301:G1-G8
19. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A 1999 Prototypic G proteincoupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 96:1569-1573 (Pubitemid 29098492)
20. Ørskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ 2005 GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 124:105-112
21. Dubé PE, Forse CL, Bahrami J, Brubaker PL 2006 The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 131:589-605 (Pubitemid 44142460)
22. Yusta B, Holland D, Koehler JA, Maziarz M, Estall JL, Higgins R, Drucker DJ 2009 ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology 137:986-996
23. Dickson L, Finlayson K 2009 VPAC and PAC receptors: From ligands to function. Pharmacol Ther 121:294-316
24. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H 2009 Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283-357
25. Moody TW, Ito T, Osefo N, Jensen RT 2011 VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr Opin Endocrinol Diabetes Obes 18:61-67
26. Sigalet DL, Wallace L, De Heuval E, Sharkey KA 2010 The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation. Neurogastroenterol Motil 22:1318-e350
27. Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelievre V, Hu Z, Liu X, Waschek JA 2003 Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am J Physiol Regul Integr Comp Physiol 285:R939-R949 (Pubitemid 37296344)
28. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, Brenneman DE 1991 An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther 257:959-966
29. Cooper HS, Murthy SN, Shah RS, Sedergran DJ 1993 Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238-249
30. Bahrami J, Yusta B, Drucker DJ 2010 ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. Gastroenterology 138:2447-2456
31. Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ 2008 Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Research 68:7897-7904
32. Amato A, Baldassano S, Serio R, Mulè F 2009 Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release. Am J Physiol Gastrointest Liver Physiol 296:G678-G684
33. Potten CS, Owen G, Hewitt D, Chadwick CA, Hendry H, Lord BI,Woolford LB 1995 Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors. Gut 36:864-873
34. Lee SJ, Lee J, Li KK, Holland D, Maughan H, Guttman DS, Yusta B, Drucker DJ 2012 Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis. Endocrinology 153:1141-1151
35. Bevins CL, Salzman NH 2011 Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 9:356-368
36. Lelievre V, Favrais G, Abad C, Adle-Biassette H, Lu Y, Germano PM, Cheung-Lau G, Pisegna JR, Gressens P, Lawson G, Waschek JA 2007 Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides 28:1688-1699 (Pubitemid 47361426)
37. Abad C, Tan YV, Lopez R, Nobuta H, Dong H, Phan P, Feng JM, Campagnoni AT, Waschek JA 2010 Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 107:19555-19560
38. -/-) mice with cyclophosphamide (CYP)-induced cystitis. J Mol Neurosci 36:188-199
39. Martin B, Shin YK, White CM, Ji S, Kim W, Carlson OD, Napora JK, Chadwick W, Chapter M, Waschek JA, Mattson MP, Maudsley S, Egan JM 2010 Vasoactive intestinal peptide-null mice demonstrate enhanced sweet taste preference, dysglycemia, and reduced taste bud leptin receptor expression. Diabetes 59:1143-1152
40. Fabricius D, Karacay B, Shutt D, Leverich W, Schafer B, Takle E, Thedens D, Khanna G, Raikwar S, Yang B, Desmond ME, O'Dorisio MS 2011 Characterization of intestinal and pancreatic dysfunction in VPAC1-null mutant mouse. Pancreas 40:861-871
41. Yadav M, Huang MC, Goetzl EJ 2011 VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1)Gprotein-coupled receptor mediation of VIP enhancement of murine experimental colitis. Cell Immunol 267:124-132
42. Ferencz A, Nedvig K, Fekecs T, Rácz B, Wéber G, Hashimoto H, Baba A, Helyes Z, Reglödi D 2010 Comparison of intestinal cold preservation injury on pituitary adenylate cyclase-activating polypeptide in knockout and wild-type mice. Transplant Proc 42:2290-2292
43. Azuma YT, Hagi K, Shintani N, Kuwamura M, Nakajima H, Hashimoto H, Baba A, Takeuchi T 2008 PACAP provides colonic protection against dextran sodium sulfate induced colitis. J Cell Physiol 216:111-119 (Pubitemid 351813101)
44. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D, Hadsell DL, Nichols BL, Burrin DG2006 GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130:150-164 (Pubitemid 43049845)
45. Gozes I, Meltzer E, Rubinrout S, Brenneman DE, Fridkin M 1989 Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. Endocrinology 125:2945-2949 (Pubitemid 20010669)
46. Gozes I, Brenneman DE 1989 VIP: molecular biology and neurobiological function. Mol Neurobiol 3:201-236